Valuation: Lundbeck

Market Cap 40.37B 6.15B 5.39B 5.01B 4.61B 8.7B 588B 8.88B 59.64B 23.38B 289B 23.07B 22.58B 998B P/E 2026 *
9.16x
P/E 2027 * 9.11x
Enterprise Value 44.45B 6.77B 5.94B 5.51B 5.07B 9.58B 647B 9.78B 65.68B 25.75B 318B 25.41B 24.86B 1,099B EV / Sales 2026 *
1.72x
EV / Sales 2027 * 1.56x
Free-Float
30.76%
Yield 2026 *
3.59%
Yield 2027 * 3.67%
1 day-1.13%
1 week-1.30%
Current month-0.18%
1 month-2.65%
3 months+5.18%
6 months-3.31%
Current year-1.47%
1 week 5.59
Extreme 5.59
5.85
1 month 5.54
Extreme 5.545
5.92
Current year 4.85
Extreme 4.852
6.26
1 year 4.48
Extreme 4.476
6.4
3 years 3.67
Extreme 3.666
6.62
5 years 3.26
Extreme 3.259
8.85
10 years 3.26
Extreme 3.259
8.85
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2023
Director of Finance/CFO 49 01/09/2022
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 25/03/2015
Director/Board Member 66 25/03/2015
Director/Board Member 60 20/03/2018
Change 5-day change 1-year change 3-year change Capi.($)
-1.13%-1.30% - - 6.25B
+0.78%+3.30%+14.47%+98.71% 94.36B
-0.91%-2.21%+45.16%+149.72% 55.23B
+3.55%+4.66%+2.10%+269.62% 22.56B
+1.24%+1.30%-14.05%-22.35% 8.01B
-0.75%-2.96%-27.34%-35.23% 7.6B
+0.72%+0.66%-10.56%-27.84% 6.66B
+0.81%+1.22%-0.23%+23.95% 5.36B
+1.00%+2.43%-5.24%-6.08% 3.68B
+0.95%+0.59%+12.25%+16.43% 3.34B
Average +0.63%+0.59%+1.84%+51.88% 22.98B
Weighted average by Cap. +0.55%+0.98%+17.10%+112.16%

Financials

2026 *2027 *
Net sales 25.79B 3.93B 3.45B 3.2B 2.94B 5.56B 376B 5.67B 38.1B 14.94B 184B 14.74B 14.42B 638B 25.87B 3.94B 3.46B 3.21B 2.95B 5.57B 377B 5.69B 38.22B 14.98B 185B 14.78B 14.47B 640B
Net income 4.55B 694M 608M 565M 520M 981M 66.3B 1B 6.73B 2.64B 32.55B 2.6B 2.55B 113B 4.6B 700M 614M 570M 525M 990M 66.94B 1.01B 6.79B 2.66B 32.87B 2.63B 2.57B 114B
Net Debt 4.09B 623M 546M 507M 467M 881M 59.53B 899M 6.04B 2.37B 29.23B 2.34B 2.29B 101B -44.13M -6.72M -5.9M -5.47M -5.04M -9.51M -643M -9.71M -65.21M -25.56M -316M -25.23M -24.69M -1.09B
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change
13/07/26 EUR 5.595 -1.67%
10/07/26 EUR 5.690 -1.13%
09/07/26 EUR 5.755 -0.95%
08/07/26 EUR 5.810 -0.68%
07/07/26 EUR 5.850 +1.56%
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
42.48DKK
Average target price
47.62DKK
Spread / Average Target
+12.11%

Quarterly revenue - Rate of surprise